Study of the Efficacy of ESTRATEST® H.S. Tablets in Relieving Menopausal Symptoms in Estrogenized Postmenopausal Women

Sponsor
Solvay Pharmaceuticals (Industry)
Overall Status
Completed
CT.gov ID
NCT00141570
Collaborator
(none)
350
77
36
4.5
0.1

Study Details

Study Description

Brief Summary

To determine whether treatment with ESTRATEST® H.S. Tablets is superior to treatment with esterified estrogens tablets

Condition or Disease Intervention/Treatment Phase
  • Drug: esterified estrogens 0.625 mg and methyltestosterone 1.25 mg
Phase 2

Study Design

Study Type:
Interventional
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double
Primary Purpose:
Treatment
Official Title:
A Multi-Center, Double-Blind Study to Determine the Efficacy of ESTRATEST® H.S. Tablets in Relieving Menopausal Symptoms in Estrogenized Postmenopausal Women
Study Start Date :
Jun 1, 2004
Actual Primary Completion Date :
Jun 1, 2007
Actual Study Completion Date :
Jun 1, 2007

Outcome Measures

Primary Outcome Measures

  1. Change from baseline in the total score of the Menopause Rating Scale (MRS) at Week 12 []

Secondary Outcome Measures

  1. Change from baseline in the MRS at Week 12 & monthly change from baseline to Week 12 in the MENQOL; Comparison of changes in SHBG & testosterone & how these changes correlate with the MRS []

Eligibility Criteria

Criteria

Ages Eligible for Study:
30 Years to 65 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:

Menopausal women between the ages of 30 and 65 years (inclusive) with symptoms of estrogen and/or androgen deficiency not currently controlled by estrogen therapy as determined by patient report and the Investigator's clinical judgement

Contacts and Locations

Locations

Site City State Country Postal Code
1 Site 66 Huntsville Alabama United States
2 Site 57 Mobile Alabama United States
3 Site 46 Montgomery Alabama United States
4 Site 29 Phoenix Arizona United States
5 Site 15 Tucson Arizona United States
6 Site 3 Jonesboro Arkansas United States
7 Site 22 Little Rock Arkansas United States
8 Site 68 Carmichael California United States
9 Site 55 Encinitas California United States
10 Site 6 San Diego California United States
11 Site 45 Santa Rosa California United States
12 Site 25 Walnut Creek California United States
13 Site 26 Denver Colorado United States
14 Site 1 Groton Connecticut United States
15 Site 54 Hartford Connecticut United States
16 Site 30 Trumbull Connecticut United States
17 Site 34 Waterbury Connecticut United States
18 Site 10 Aventura Florida United States
19 Site 73 Ft. Myers Florida United States
20 Site 51 Leesburg Florida United States
21 Site 49 Melbourne Florida United States
22 Site 64 New Port Richey Florida United States
23 Site 61 Ocala Florida United States
24 Site 27 Palm Springs Florida United States
25 Site 11 Pinellas Park Florida United States
26 Site 75 Sarasota Florida United States
27 Site 69 St. Petersburg Florida United States
28 Site 70 Venice Florida United States
29 Site 17 West Palm Beach Florida United States
30 Site 50 Alpharetta Georgia United States
31 Site 5 Atlanta Georgia United States
32 Site 44 Decatur Georgia United States
33 Site 77 Douglasville Georgia United States
34 Site 9 Riverdale Georgia United States
35 Site 7 Savannah Georgia United States
36 Site 47 Boise Idaho United States
37 Site 24 Champaign Illinois United States
38 Site 20 Chicago Illinois United States
39 Site 76 Peoria Illinois United States
40 Site 58 Evansville Indiana United States
41 Site 39 Wichita Kansas United States
42 Site 59 Baton Rouge Louisiana United States
43 Site 52 New Orleans Louisiana United States
44 Site 53 Ann Arbor Michigan United States
45 Site 63 Kansas City Missouri United States
46 Site 32 Richmond Heights Missouri United States
47 Site 36 St. Louis Missouri United States
48 Site 72 Billings Montana United States
49 Site 21 Lincoln Nebraska United States
50 Site 37 Reno Nevada United States
51 Site 65 Cary North Carolina United States
52 Site 13 New Bern North Carolina United States
53 Site 16 Winston-Salem North Carolina United States
54 Site 60 Columbus Ohio United States
55 Site 67 Oklahoma City Oklahoma United States
56 Site 40 Tulsa Oklahoma United States
57 Site 62 Eugene Oregon United States
58 Site 41 Medford Oregon United States
59 Site 33 Portland Oregon United States
60 Site 18 Erie Pennsylvania United States
61 Site 19 Philadelphia Pennsylvania United States
62 Site 23 Pottstown Pennsylvania United States
63 Site 31 Anderson South Carolina United States
64 Site 35 Greer South Carolina United States
65 Site 4 Chattanooga Tennessee United States
66 Site 74 Conroe Texas United States
67 Site 8 Corpus Christi Texas United States
68 Site 71 Dallas Texas United States
69 Site 42 Houston Texas United States
70 Site 14 San Antonio Texas United States
71 Site 38 Salt Lake City Utah United States
72 Site 28 Norfolk Virginia United States
73 Site 12 Richmond Virginia United States
74 Site 56 Renton Washington United States
75 Site 2 Seattle Washington United States
76 Site 48 Spokane Washington United States
77 Site 43 Tacoma Washington United States

Sponsors and Collaborators

  • Solvay Pharmaceuticals

Investigators

  • Study Director: Global Clinical Director Solvay, Solvay Pharmaceuticals

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
, ,
ClinicalTrials.gov Identifier:
NCT00141570
Other Study ID Numbers:
  • S030.2.106
First Posted:
Sep 1, 2005
Last Update Posted:
Jan 16, 2015
Last Verified:
Jan 1, 2009

Study Results

No Results Posted as of Jan 16, 2015